References
- Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain 1980;103:259-80. https://doi.org/10.1093/brain/103.2.259
- Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 1974;6:98-118.
- Lupski JR, Garcia CA. Charcot-Marie-Tooth peripheral neuropathies and related disorders. In: Scriver CR, ed. The metabolic and molecular bases of inherited disease. Volume 4. 8th ed. New York: McGraw Hill, 2001:5759-88.
- Patzko A, Shy ME. Update on Charcot-Marie-Tooth disease. Curr Neurol Neurosci Rep 2011;11:78-88. https://doi.org/10.1007/s11910-010-0158-7
- Hanemann CO. Hereditary demyelinating neuropathies: from gene to disease. Neurogenetics 2001;3:53-7. https://doi.org/10.1007/s100480000102
- Lupski JR, Garcia CA, Parry GJ, Patel PI. Charcot-Marie-Tooth polyneuropathy syndrome: clinical, electrophysiological, and genetic aspects. In: Appel SH, ed. Current neurology. Chicago: Mosby-Yearbook, 1991:1-25.
- Liu P, Gelowani V, Zhang F, Drory VE, Ben-Shachar S, Roney E, et al. Mechanism, prevalence, and more severe neuropathy phenotype of the Charcot-Marie-Tooth type 1A triplication. Am J Hum Genet 2014;94:462-9. https://doi.org/10.1016/j.ajhg.2014.01.017
- Snipes GJ, Suter U, Welcher AA, Shooter EM. Characterization of a novel peripheral nervous system myelin protein (PMP-22/SR13). J Cell Biol 1992;117:225-38. https://doi.org/10.1083/jcb.117.1.225
- Spreyer P, Kuhn G, Hanemann CO, Gillen C, Schaal H, Kuhn R, et al. Axon-regulated expression of a Schwann cell transcript that is homologous to a 'growth arrest-specific' gene. EMBO J 1991;10:3661-8.
- Lemke G. Molecular biology of the major myelin genes. Trends Neurosci 1986;9:266-70. https://doi.org/10.1016/0166-2236(86)90076-7
- Sutcliffe JG. The genes for myelin. Trends Genet 1987;3:73-6. https://doi.org/10.1016/0168-9525(87)90179-X
- Tobler AR, Notterpek L, Naef R, Taylor V, Suter U, Shooter EM. Transport of Trembler-J mutant peripheral myelin protein 22 is blocked in the intermediate compartment and affects the transport of the wild-type protein by direct interaction. J Neurosci 1999;19:2027-36. https://doi.org/10.1523/JNEUROSCI.19-06-02027.1999
- Myers JK, Mobley CK, Sanders CR. The peripheral neuropathy-linked Trembler and Trembler-J mutant forms of peripheral myelin protein 22 are folding-destabilized. Biochemistry 2008;47:10620-9. https://doi.org/10.1021/bi801157p
- Sakakura M, Hadziselimovic A, Wang Z, Schey KL, Sanders CR. Structural basis for the Trembler-J phenotype of Charcot-Marie-Tooth disease. Structure 2011;19:1160-9. https://doi.org/10.1016/j.str.2011.05.009
- Pareek S, Notterpek L, Snipes GJ, Naef R, Sossin W, Laliberte J, et al. Neurons promote the translocation of peripheral myelin protein 22 into myelin. J Neurosci 1997;17:7754-62. https://doi.org/10.1523/JNEUROSCI.17-20-07754.1997
- Sancho S, Young P, Suter U. Regulation of Schwann cell proliferation and apoptosis in PMP22-deficient mice and mouse models of Charcot-Marie-Tooth disease type 1A. Brain 2001;124:2177-87. https://doi.org/10.1093/brain/124.11.2177
- Khajavi M, Inoue K, Wiszniewski W, Ohyama T, Snipes GJ, Lupski JR. Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants. Am J Hum Genet 2005;77:841-50. https://doi.org/10.1086/497541
- Brockes JP, Fields KL, Raff MC. Studies on cultured rat Schwann cells. I. Establishment of purified populations from cultures of peripheral nerve. Brain Res 1979;165:105-18. https://doi.org/10.1016/0006-8993(79)90048-9
- Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004;10:396-401. https://doi.org/10.1038/nm1023
- Pareyson D, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, et al; CMT-TRIAAL; CMT-TRAUK groups. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 2011;10:320-8. https://doi.org/10.1016/S1474-4422(11)70025-4
- Pleasure DE, Chance PF. Neurotrophin-3 therapy for Charcot-MarieTooth disease type 1A. Neurology 2005;65:662-3. https://doi.org/10.1212/01.wnl.0000179404.82539.d7
- Sahenk Z, Galloway G, Edwards C, Malik V, Kaspar BK, Eagle A, et al. TrkB and TrkC agonist antibodies improve function, electrophysiologic and pathologic features in Trembler J mice. Exp Neurol 2010;224:495-506. https://doi.org/10.1016/j.expneurol.2010.05.013
- Jang SW, Lopez-Anido C, MacArthur R, Svaren J, Inglese J. Identification of drug modulators targeting gene-dosage disease CMT1A. ACS Chem Biol 2012;7:1205-13. https://doi.org/10.1021/cb300048d
- Pennuto M, Tinelli E, Malaguti M, Del Carro U, D'Antonio M, Ron D, et al. Ablation of the UPR-mediator CHOP restores motor function and reduces demyelination in Charcot-Marie-Tooth 1B mice. Neuron 2008;57:393-405. https://doi.org/10.1016/j.neuron.2007.12.021
- Khajavi M, Shiga K, Wiszniewski W, He F, Shaw CA, Yan J, et al. Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: a potential therapy for inherited neuropathy. Am J Hum Genet 2007;81:438-53. https://doi.org/10.1086/519926
- Pahl HL. Signal transduction from the endoplasmic reticulum to the cell nucleus. Physiol Rev 1999;79:683-701. https://doi.org/10.1152/physrev.1999.79.3.683